METABOLIC DISORDERS: ANIMAL MODELS
In metabolic disorders such as diabetes mellitus or obesity, a modification of the fecal flora, an increase of the bacterial translocation, or a decrease in the integrity of the intestinal barrier, is observed. The worldwide obesity epidemic contributes to the increasing incidence of a number of diseases, as Non-Alcoholic Fatty-Liver Disease (NAFLD) and its most severe form, the Non-Alcoholic-Steato-Hepatitis (NASH).
Probiotic treatment reduces blood glucose levels in diabetic rats
Data on the prevalence of NASH has varied from 18.5% (5) to 69% (43) in obesity (de Oliveira, Ann Hepatol, 2007). Recently, it has been demonstrated that probiotic treatment reduces blood glucose levels in diabetic rats (Al-Salami, 2008) and improves high-fat-diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells.
We are able to characterize adipogenic properties of ligands or nutriments in vitro and in vivo, and to evaluate the integrity of the intestinal barrier and the modification of the fecal flora or bacterial translocation in the model of obese and/or diabetic mice.
Evaluating in vitro effects
We can evaluate the in vitro effects of ligands or nutriments on adipocyte differentiation using 3T3-L1 cells and specific coloration or quantification of specific gene expression. In vivo, several animal models are available: genetically modified animal model (ob/ob, db/db); obese and diabetic mice induced by high-fat diet associated tools; conventional bacteriologic analysis of the flora and the bacterial translocation; evaluation of intestinal barrier integrity (FITC-dextran, lactulose/mannitol test, expression of specific gene by real-time PCR, IHC or WB); dosage of lipidemia, glycemia by conventional biochemical analysis; and a test of insulin resistance.